By:mortalmyth 06 Feb 2013, 03:19 PM CST Msg. 6433 of 6439

New Post Public Reply Private Reply Replies (1) Message Board

Feb 6, 2013 at 3:56 PM

By: mortalmyth
06 Feb 2013, 03:19 PM CST Msg. 6433 of 6439
(Msg. is a reply to 6406 by andrewinvestor.) andrewinvestor, and to think you eat with that mouth. Utterly amazing.

Now how about stepping up to the plate and answering some questions?

1) Where do these financing companies called Quixstone Investments, Inc. and Duvernoi Capital Investments Inc. reside and who are the principles involved?

As noted in the SEC investigation letter, the accuracy of SRGE PR content and the company’s business operations and arrangements are in serious question. SRGE has two financing companies that can't be found anywhere, but in their press releases. Where do these companies called Quixstone Investments, Inc. and Duvernoi Capital Investments Inc. reside and who are the principles involved? Internet searches and business directory serches have come up empty. Hopefully the SEC investigation will force clarification and disclosure of this anomaly.

2) Who has heard of a legit company stopping payment of a dividend past its ex-date (this must be some kind of record)?

The second dividend was postponed for three weeks before SRGE finally publicly acknowledged the fact in a PR, and they still didn't divulge the real reason for this letdown to the downtrodden shareholders. It's quite likely they didn't have enough money because they were unable to unload enough shares to pay for it due to the timely SEC suspension on Dec. 28th. The trading volume is now drying up as expected while trading on the grey sheets, so don't expect the company to sell enough shares any time soon to get the money needed for paying the second dividend for those that didn't get one, and for the next quarterly dividend. All are forward looking statements and if the company backed out of the last who's to say they won't again? Who has heard of a legit company stopping payment of a dividend past its ex-date (this must be some kind of record)? This action is irresponsible, is in direct violation of fiduciary responsibility, and makes the company libel to the shareholders that didn't receive the second dividend.

3) Do you find it suspect that a research company supposedly being in business since 2001 has only one research report available on the web and it is for SRGE? Do you find it suspect that a supposed real company in business since 2001 would not have a web presence until 2011, oddly just before their SRGE report release in Jan. 2012?

The research company Mathers Research indicates it has been in business since 2001, but they evidently have only produced one report in all this time, that being just for SRGE. This is considered very odd to say the least. Also, their website wasn't created until 2011, oddly just before publishing the Jan. 2012 report and touting that SRGE should obtain a share price of $0.20 in 2012. Before you get too excited about becoming an instant millionaire, you might want to read their disclaimer and just where they source their information. Also, take a look at the timing of their SRGE report and the stock trading just before and during Jan. 2012.

http://www.mathersresearch.com

4) Where is the SRGE CEO background info and why haven't you or even one other advocate provided this to the board?

SRGE has a phantom CEO that doesn't exist except in press releases. Although many have scoured the internet, no biography, education and work experience history information can be found for SRGE CEO Mr. Davies' (or Davis'). Even the SRGE advocates can't such info and have yet to provide any data to prove their case of his existence. As such, many believe this individual is just an incarnate of Mr. Smid (Mr. Smid has a less than admirable background and evidently has direct ties to SRGE through an outstanding payable loan).

5) Where do these companies called Rockridge Capital Holdings Corporation and Novamex Minerals S.A. reside and who are the principles?

As noted in the SEC investigation letter, the accuracy company’s business operations and arrangements are in serious question. Rockridge Capital Holdings Corporation and Novamex Minerals S.A. can only be found in SRGE documents. Internet searches and business directory searches have come up empty. Hopefully the SEC investigation will force clarification and disclosure of this anomaly.

6) Do you believe SRGE is truly destined for an uplisting or moving to another trading exchange?

There are rumors about SRGE getting an uplisting or maybe moving to another trading exchange (with SRGE shares to be valued at an unbelievable $2.50). All this talk is unfounded and extremely unlikely to happen since SRGE has no audited financials and because of the on-going SEC investigation (which the uplisting was specifically identified). Stock exchanges communicate with one another so any SEC investigation will put a damper on any forward movement in this regard. And to believe SRGE can move off the grey sheets to some new exchange, especially since those that have any real clout require audited financials, is absurd. Of course, to also think SRGE shares will trade at $2.50 without a massive reverse split, making the SRGE market cap in-line with some of the biggest of the major miners, is insanity at its finest. Remember, if it sounds too good to be true, it probably is.

Thanks for any inputs to the above questions.

Southridge Enterprises Inc. (SRGE) Stock Research Links

SRGE Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...